Fig. 7: Mass response assessment of drug sensitivity for various cancer specimen formats. | Communications Biology

Fig. 7: Mass response assessment of drug sensitivity for various cancer specimen formats.

From: A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements

Fig. 7

Mass response measurements were collected for a plasma cell leukemia (PCL) cells isolated from a peripheral blood sample and treated for 15 h with the drugs listed, b multiple myeloma cells isolated from a bone marrow aspirate sample and treated for 15 h with the drugs listed, c cells isolated from fine-needle aspirate (FNA) samples collected from a lung mass, neck mass, and soft tissue bone mass in three different patients with non-small cell lung cancer, melanoma, and breast cancer, respectively, and treated for 20 h with the drugs listed, and d non-small cell lung cancer (NSCLC) cells isolated from a pleural effusion sample and treated for 20 h with the drugs listed. For all plots, each point represents the mass response measured in an individual instrument, with error bars corresponding to the 95% confidence interval for mass response defined by 5000 random samples of 2500 cells. *** indicates p < 0.001, ** indicates p < 0.01, * indicates p < 0.05, ns indicates p > 0.05.

Back to article page